@article {8908, title = {is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing.}, journal = {Blood Cancer Discov}, volume = {2}, year = {2021}, month = {2021 Sep}, pages = {500-517}, abstract = {

Clonal hematopoiesis results from somatic mutations in cancer driver genes in hematopoietic stem cells. We sought to identify novel drivers of clonal expansion using an unbiased analysis of sequencing data from 84,683 persons and identified common mutations in the 5-methylcytosine reader, , as well as in , , and . We also identified these mutations at low frequency in myelodysplastic syndrome patients. edited mouse hematopoietic stem and progenitor cells exhibited a competitive advantage and increased genome-wide intron retention. mutations potentially link DNA methylation and RNA splicing, the two most commonly mutated pathways in clonal hematopoiesis and MDS.

}, issn = {2643-3249}, doi = {10.1158/2643-3230.BCD-20-0224}, author = {Beauchamp, Ellen M and Leventhal, Matthew and Bernard, Elsa and Hoppe, Emma R and Todisco, Gabriele and Creignou, Maria and Gall{\`\i}, Anna and Castellano, Cecilia A and McConkey, Marie and Tarun, Akansha and Wong, Waihay and Schenone, Monica and Stanclift, Caroline and Tanenbaum, Benjamin and Malolepsza, Edyta and Nilsson, Bj{\"o}rn and Bick, Alexander G and Weinstock, Joshua S and Miller, Mendy and Niroula, Abhishek and Dunford, Andrew and Taylor-Weiner, Amaro and Wood, Timothy and Barbera, Alex and Anand, Shankara and Psaty, Bruce M and Desai, Pinkal and Cho, Michael H and Johnson, Andrew D and Loos, Ruth and MacArthur, Daniel G and Lek, Monkol and Neuberg, Donna S and Lage, Kasper and Carr, Steven A and Hellstrom-Lindberg, Eva and Malcovati, Luca and Papaemmanuil, Elli and Stewart, Chip and Getz, Gad and Bradley, Robert K and Jaiswal, Siddhartha and Ebert, Benjamin L} } @article {8839, title = {Supplemental Association of Clonal Hematopoiesis With Incident Heart~Failure.}, journal = {J Am Coll Cardiol}, volume = {78}, year = {2021}, month = {2021 07 06}, pages = {42-52}, abstract = {

BACKGROUND: Age-related clonal hematopoiesis of indeterminate potential (CHIP), defined as clonally expanded leukemogenic sequence variations (particularly in DNMT3A, TET2, ASXL1, and JAK2) in asymptomatic individuals, is associated with cardiovascular events, including recurrent heart failure (HF).

OBJECTIVES: This study sought to evaluate whether CHIP is associated with incident HF.

METHODS: CHIP status was obtained from whole exome or genome sequencing of blood DNA in participants without prevalent HF or hematological malignancy from 5 cohorts. Cox proportional hazards models were performed within each cohort, adjusting for demographic and clinical risk factors, followed by fixed-effect meta-analyses. Large CHIP clones (defined as variant allele frequency >10\%), HF with or without baseline coronary heart disease, and left ventricular ejection fraction were evaluated in secondary analyses.

RESULTS: Of 56,597 individuals (59\% women, mean age 58 years at baseline), 3,406 (6\%) had CHIP, and 4,694 developed HF (8.3\%) over up to 20 years of follow-up. CHIP was prospectively associated with a 25\% increased risk of HF in meta-analysis (hazard ratio: 1.25; 95\% confidence interval: 1.13-1.38) with consistent associations across cohorts. ASXL1, TET2, and JAK2 sequence variations were each associated with an increased risk of HF, whereas DNMT3A sequence variations were not associated with HF. Secondary analyses suggested large CHIP was associated with a greater risk of HF (hazard ratio: 1.29; 95\% confidence interval: 1.15-1.44), and the associations for CHIP on HF with and without prior coronary heart disease were homogenous. ASXL1 sequence variations were associated with reduced left ventricular ejection fraction.

CONCLUSIONS: CHIP, particularly sequence variations in ASXL1, TET2, and JAK2, represents a new risk factor for HF.

}, keywords = {Aged, Clonal Hematopoiesis, Correlation of Data, Demography, DNA-Binding Proteins, Female, Heart Failure, Humans, Janus Kinase 2, Male, Middle Aged, Mutation, Proportional Hazards Models, Proto-Oncogene Proteins, Repressor Proteins, Risk Factors, Stroke Volume, Ventricular Dysfunction, Left, Whole Exome Sequencing}, issn = {1558-3597}, doi = {10.1016/j.jacc.2021.04.085}, author = {Yu, Bing and Roberts, Mary B and Raffield, Laura M and Zekavat, Seyedeh Maryam and Nguyen, Ngoc Quynh H and Biggs, Mary L and Brown, Michael R and Griffin, Gabriel and Desai, Pinkal and Correa, Adolfo and Morrison, Alanna C and Shah, Amil M and Niroula, Abhishek and Uddin, Md Mesbah and Honigberg, Michael C and Ebert, Benjamin L and Psaty, Bruce M and Whitsel, Eric A and Manson, JoAnn E and Kooperberg, Charles and Bick, Alexander G and Ballantyne, Christie M and Reiner, Alex P and Natarajan, Pradeep and Eaton, Charles B} } @article {8986, title = {Clonal Hematopoiesis Is Associated With Higher Risk of Stroke.}, journal = {Stroke}, volume = {53}, year = {2022}, month = {2022 Mar}, pages = {788-797}, abstract = {

BACKGROUND AND PURPOSE: Clonal hematopoiesis of indeterminate potential (CHIP) is a novel age-related risk factor for cardiovascular disease-related morbidity and mortality. The association of CHIP with risk of incident ischemic stroke was reported previously in an exploratory analysis including a small number of incident stroke cases without replication and lack of stroke subphenotyping. The purpose of this study was to discover whether CHIP is a risk factor for ischemic or hemorrhagic stroke.

METHODS: We utilized plasma genome sequence data of blood DNA to identify CHIP in 78 752 individuals from 8 prospective cohorts and biobanks. We then assessed the association of CHIP and commonly mutated individual CHIP driver genes (, , and ) with any stroke, ischemic stroke, and hemorrhagic stroke.

RESULTS: CHIP was associated with an increased risk of total stroke (hazard ratio, 1.14 [95\% CI, 1.03-1.27]; =0.01) after adjustment for age, sex, and race. We observed associations with CHIP with risk of hemorrhagic stroke (hazard ratio, 1.24 [95\% CI, 1.01-1.51]; =0.04) and with small vessel ischemic stroke subtypes. In gene-specific association results, showed the strongest association with total stroke and ischemic stroke, whereas and were each associated with increased risk of hemorrhagic stroke.

CONCLUSIONS: CHIP is associated with an increased risk of stroke, particularly with hemorrhagic and small vessel ischemic stroke. Future studies clarifying the relationship between CHIP and subtypes of stroke are needed.

}, issn = {1524-4628}, doi = {10.1161/STROKEAHA.121.037388}, author = {Bhattacharya, Romit and Zekavat, Seyedeh M and Haessler, Jeffrey and Fornage, Myriam and Raffield, Laura and Uddin, Md Mesbah and Bick, Alexander G and Niroula, Abhishek and Yu, Bing and Gibson, Christopher and Griffin, Gabriel and Morrison, Alanna C and Psaty, Bruce M and Longstreth, William T and Bis, Joshua C and Rich, Stephen S and Rotter, Jerome I and Tracy, Russell P and Correa, Adolfo and Seshadri, Sudha and Johnson, Andrew and Collins, Jason M and Hayden, Kathleen M and Madsen, Tracy E and Ballantyne, Christie M and Jaiswal, Siddhartha and Ebert, Benjamin L and Kooperberg, Charles and Manson, JoAnn E and Whitsel, Eric A and Natarajan, Pradeep and Reiner, Alexander P} } @article {9865, title = {Human Plasma Proteomic Profile of Clonal Hematopoiesis.}, journal = {bioRxiv}, year = {2024}, month = {2024 Oct 31}, abstract = {

Plasma proteomic profiles associated with subclinical somatic mutations in blood cells may offer novel insights into downstream clinical consequences. Here, we explore such patterns in clonal hematopoiesis of indeterminate potential (CHIP), which is linked to several cancer and non-cancer outcomes, including coronary artery disease (CAD). Among 61,833 ancestrally diverse participants (3,881 with CHIP) from NHLBI TOPMed and UK Biobank with blood-based DNA sequencing and proteomic measurements (1,148 proteins by SomaScan in TOPMed and 2,917 proteins by Olink in UK Biobank), we identified 32 and 345 unique proteins from TOPMed and UK Biobank, respectively, associated with the most prevalent driver genes (, , and ). These associations showed substantial heterogeneity by driver genes, sex, and race, and were enriched for immune response and inflammation pathways. Mendelian randomization in humans, coupled with ELISA in hematopoietic -/- vs wild-type mice validation, disentangled causal proteomic perturbations from CHIP. Lastly, we identified plasma proteins shared between CHIP and CAD.

}, issn = {2692-8205}, doi = {10.1101/2023.07.25.550557}, author = {Yu, Zhi and Vromman, Am{\'e}lie and Nguyen, Ngoc Quynh H and Schuermans, Art and Rentz, Thiago and Vellarikkal, Shamsudheen K and Uddin, Md Mesbah and Niroula, Abhishek and Griffin, Gabriel and Honigberg, Michael C and Lin, Amy E and Gibson, Christopher J and Katz, Daniel H and Tahir, Usman and Fang, Shi and Haidermota, Sara and Ganesh, Shriienidhie and Antoine, Tajmara and Weinstock, Joshua and Austin, Thomas R and Ramachandran, Vasan S and Peloso, Gina M and Hornsby, Whitney and Ganz, Peter and Manson, JoAnn E and Haring, Bernhard and Kooperberg, Charles L and Reiner, Alexander P and Bis, Joshua C and Psaty, Bruce M and Min, Yuan-I and Correa, Adolfo and Lange, Leslie A and Post, Wendy S and Rotter, Jerome I and Rich, Stephen S and Wilson, James G and Ebert, Benjamin L and Yu, Bing and Ballantyne, Christie M and Coresh, Josef and Sankaran, Vijay G and Bick, Alexander G and Jaiswal, Siddhartha and Gerszten, Robert E and Libby, Peter and Gupta, Rajat M and Natarajan, Pradeep} }